Analysts: Recall of St. Jude Medical’s Durata not likely, despite problems

St. Jude Medical's Durata pacemaker lead

St. Jude Medical (NYSE:STJ) isn’t likely to recall its next-generation Durata pacemaker leads despite a warning from the FDA, but the situation with the medical device company’s flagship product could change any day, according to Wall Street analysts.

Although investors have already baked the downside from the warning into the share price, meaning some potential upside for STJ shares once the problems flagged in the watchdog agency’s Form 483 warning are fixed, analysts from Leerink Swann and Jefferies & Co. told MassDevice.com today that the Durata situation is still fluid.

"The likelihood of a recall, based on what we know today, is fairly small," Leerink Swann’s Danielle Antalffy told us. "Until the device actually starts failing in a real way, like what we saw with Riata, Durata is not going get pulled."

"If one’s being intellectually honest, the probability is still quite low, given what we know," agreed Jefferies analyst Raj Denhoy. "There are a lot of reasons to believe we could see something, some problem, down the road, but clinically the product is still performing quite well. The question is, will the FDA do something despite the clinical data being quite good?"

At least 1 other analyst thinks a recall is more likely, if not downright probable. Last month, analysts at Citigroup built the potential for a recall into their model, leading to a downgrade for St. Jude and upgrades for rivals Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT).

St. Paul-based St. Jude could see its earnings per share lose $1.27 if it’s compelled to yank the beleaguered Durata leads, the medical device company’s next-generation series of wires that are threaded through blood vessels and into the heart.

Also in November, the FDA released a report slamming St. Jude for multiple problems at its Durata plant in Sylmar, Calif., driving STJ shares to a 52-week low of $30.25 before closing at $31.76, down 7.1%.

Antalffy and Denhoy also agreed that St. Jude faces other headwinds, including the general cardiac rhythm management slump that’s affected the entire sector and a diminished confidence in its pipeline of future products. Both analysts cited the failure of a clinical trial for STJ’s Amplatzer heart implant as a factor in The Street’s perception of the pipeline.

"The bigger issue is that their reputation for a robust pipeline has suffered," Denhoy said. "It has become a story that’s been tethered to this Riata/Durata issue."

"I still believe in the pipeline story, but obviously with the Respect trial not living up to expectations, that’s a potentially a pipeline product that goes away. I still tend to think it might get approved, but even with approval adoption is an issue," Antalffy noted.

Another red flag is the deteriorating relationship between CEO Daniel Starks and the investment community, she said.

"Management’s communication with The Street has been poor the last 2 quarters," Antalffy said. "We’ll get a lot of answers at the Feb. 1 analysts’ meeting. I’m not sure what to expect."

On the positive side for investors, she added, is a $1 billion stock buyback that’s already under way and a promising outlook for St. Jude’s fractional flow reserve technology, called PressureWire.

"FFR is definitely viewed favorably, as a potentially sustainable double-digit growth market with Fame 2 results now in hand and the increasing need to document and justify procedures," Antalffy told us.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Comments

  1. says

    I simply want to tell you that I’m new to weblog and actually savored you’re web-site. Very likely I’m want to bookmark your website . You definitely have really good articles and reviews. Regards for revealing your website.

Trackbacks

  1. … [Trackback]

    […] Informations on that Topic: massdevice.com/analyst-recall-st-jude-medicals-durata-not-likely-despite-problems/ […]

  2. My name is Eko Priyanto

    Apakah ibu membutuhkan obat herbal de Nature Indonesia silahkan bisa hubungi customer service kami secara langsung via SMS ataupun Telepon. Kami selalu online 24 jam untuk melayani pemesanan produk herbal de Nature.

Leave a Reply